DexCom (DXCM) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DexCom (DXCM) has outperformed Penumbra (PEN) over the past year, gaining 27.7% versus a gain of 27.0%. Over five years, PEN leads with a +18.2% price change compared with -38.1% for DXCM. DexCom is the larger company by market cap ($31.81 billion vs $12.46 billion), about 2.6 times the size, while Penumbra is growing revenue faster (+17.5% vs +15.6%).
On valuation, DexCom trades at a lower forward P/E (27.0x vs 51.6x for Penumbra). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | PEN |
|---|---|---|
| Share price | $84.30 | $316.35 |
| Market cap | $31.81B | $12.46B |
| 1-day change | +1.09% | -0.22% |
| YTD return | +27.02% | +1.75% |
| 1-year return | +27.67% | +27.03% |
| 5-year return | -38.07% | +18.15% |
| P/E ratio (TTM) | 33.45 | 77.73 |
| Forward P/E | 26.96 | 51.59 |
| EPS (TTM) | $2.52 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.66B | $1.40B |
| Revenue growth (YoY) | +15.60% | +17.50% |
| Net income (latest FY) | $836.30M | $177.69M |
| Gross margin | 60.10% | 67.14% |
| Operating margin | 19.56% | 13.48% |
| Net margin | 17.94% | 12.66% |
| 52-week high | $92.59 | $362.41 |
| 52-week low | $54.11 | $221.26 |
| Distance from 52-week high | -8.95% | -12.71% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +14.15% | +14.30% |
| Average volume | 4.47M | 343.03K |
| Shares outstanding | 377.36M | 39.39M |
| Employees | 11,000 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 2.6 times larger than Penumbra by market value ($31.81B vs $12.46B).
- Penumbra trades at a higher earnings multiple (77.7x vs 33.5x trailing P/E).
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 12.7 cents for Penumbra.
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
DXCM vs PEN FAQ
Which is bigger, DexCom or Penumbra?
DexCom (DXCM) is larger, with a market capitalization of $31.81B compared with $12.46B for Penumbra (PEN).
Which stock has performed better over the past year, DXCM or PEN?
DXCM returned +27.67% over the past 12 months, compared with +27.03% for PEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or PEN?
DXCM has the lower trailing P/E at 33.5, versus 77.7 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are DexCom and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.